Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- , ...
Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback